The free radical scavenger edaravone is able to stimulate prostacyclin release and inhibit the lipoxygenase pathway in the arachidonic acid cascade. The effect of edaravone administration on myocardial damage in rabbit hearts subjected to ischaemia-reperfusion was examined at different times relative to reperfusion. All rabbits underwent sustained coronary artery occlusion for 30 min followed by 3 h of reperfusion. Rabbits were divided into the following groups: control; early (3 mg/kg edaravone IV 10 min before reperfusion); immediate (3 mg/kg edaravone IV immediately after the start of reperfusion); and late (3, 6 or 10 mg/kg edaravone IV 5 min after the start of reperfusion). Single bolus administration of edaravone 10 min before reperfusion or immediately upon initiation of reperfusion appears to be associated with reductions in infarction size and the percentage of apoptotic cells, but treatment with edaravone 5 min after initiation of reperfusion does not appear to have this protective effect.
Introduction
Various types of free radical scavengers and antioxidants have been shown to reduce reperfusion injury effectively. However, these all have limitations as therapeutic agents for reperfusion-induced injury, mainly as a result of low tissue penetration or rapid clearance from the body. Edaravone, a newly developed antioxidant which has hydroxyl radical scavenging activity and inhibits irondependent lipid peroxidation, has been shown to reduce brain oedema in cerebral ischaemia through the inhibition of the lipoxygenase pathway of arachidonic acid.
Following a period of ischaemia, restoration of flow by coronary reperfusion is accompanied by myocardial injury, via the release of potent reactive oxygen species, Effect of edaravone treatment on reperfusion injury which directly influences the degree of recovery and eventually leads to cellular death by necrosis and apoptosis.
Recent reports have shown myocardial protection with edaravone in rabbit hearts subjected to ischaemia-reperfusion. Di Paola et al. 1 have also demonstrated that metabolites of arachidonic acid cause the release of cytochrome c from mitochondria by opening the permeability transition pore. However, to the authors' knowledge, there have been no reports that evaluate edaravone treatment after reperfusion. We examined the effect of edaravone administration at different time points relative to reperfusion on myocardial damage in the rabbit heart subjected to ischaemia-reperfusion.
Materials and methods

ANIMAL CARE
This study was carried out on male New Zealand white rabbits (2.5 -3.2 kg body weight) maintained on a standard diet. Animals were cared for and used in accordance with the guidelines of the Committee on Animals of Kanazawa Medical University.
DRUGS AND CHEMICALS
Edaravone was purchased from Mitsubishi Pharma Corporation (Osaka, Japan). Superoxide dismutase and triphenyltetrazolium chloride (TTC) were obtained from Sigma Chemical (St Louis, Missouri, USA). Unisperse ® blue dye was purchased from Ciba Specialty Chemicals (Tarrytown, New York, USA).
SURGICAL PREPARATION
The animals were anaesthetized with an intramuscular injection of ketamine hydrochloride (35 mg/kg) and xylazine (5 mg/kg). Further injections of ketamine-xylazine were given as needed throughout the surgical procedure. The animals were intubated and ventilated with a positive-pressure ventilator. Catheters were placed in the left carotid artery and the jugular vein for blood pressure monitoring and drug infusion, respectively. Electrocardiographic leads were attached to subcutaneous electrodes to monitor heart rhythm.
MYOCARDIAL
ISCHAEMIA-REPERFUSION
All surgical procedures were performed under sterile conditions. The chest was opened by a left thoracotomy in the fourth intercostal space, and the pericardium was opened to expose the heart. A 5-0 silk suture with an atraumatic needle was then passed around the left anterior descending artery (LAD) midway between the atrioventricular groove and the apex of the heart. The animal was then heparinized with 500 U of heparin sodium to prevent thrombosis. The ends of the suture were passed through a small, hollow plastic tube, which was tapered at one end. Myocardial ischaemia was confirmed visually in situ by regional cyanosis, electrocardiograph S-T elevation/depression or T-wave inversion, hypokinetic movement of the myocardium, and relative hypotension. The LAD was occluded. After 30 min of ischaemia, the ligature was released and the heart was allowed to reperfuse for 3 h.
EXPERIMENT PROTOCOL
The experimental design is illustrated in Fig. 1 . All animals were subjected to 30 min of regional ischaemia induced by occlusion of the LAD followed by 3 h of reperfusion. The animals were divided into the following groups: control; early edaravone (3 mg/kg IV 10 min before reperfusion); immediate edaravone (3 mg/kg IV immediately after the start of reperfusion); and late edaravone (3, 6 or 10 mg/kg IV 5 min after the start of reperfusion).
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MEASUREMENT OF INFARCT SIZE
At the end of each experiment, the LAD was re-occluded and 50% Unisperse ® blue dye solution was injected into the right jugular vein until the eyes turned blue. This was to distinguish between perfused and nonperfused (risk area) regions of the myocardium. The Unisperse ® blue solution stains the perfused myocardium, while the occluded vascular bed remains uncoloured. The animal was then killed and the heart removed. Heart slices were incubated at room temperature for 20 min in a 1% solution of TTC. After staining, the infarct area (no TTC staining) and risk area (no Unisperse ® blue staining) were determined by computer morphometry using Bioquant imaging software (Bioquant Imaging, Nashville, Tennessee, USA), and the percentages of infarcted and risk areas were calculated.
IN SITU IDENTIFICATION OF NUCLEAR DNA FRAGMENTATION
After deparaffinization, the tissue sections were stained using the terminal deoxynucleotidyl transferase-mediated biotin nick end-labelling (TUNEL) method, and in situ apoptosis-induced nuclear DNA fragmentation was determined by use of a fluorescence assay. 2 -4 Apoptotic cardiomyocyte nuclei were examined under a fluorescence microscope after 30 min of FIGURE 1: Study design. Regional ischaemia of duration 30 min was induced by occlusion of the left anterior descending artery, and was followed by 3 h of reperfusion. Early, edaravone (3 mg/kg) IV 10 min before the start of reperfusion; Immediate, edaravone (3 mg/kg) IV immediately after the start of reperfusion; Late, edaravone (3, 6 or 10 mg/kg) IV 5 min after the start of reperfusion 
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ischaemia followed by 3 h of reperfusion. The percentage of apoptotic cardiomyocyte nuclei was determined microscopically using an eyepiece grid (× 200). Quantitative analysis of DNA fragmentation was performed using the TUNEL method at the single-cell level. The percentage of TUNEL-positive cardiomyocyte nuclei was determined microscopically using an eyepiece grid (× 200). Five microscopic fields per section were selected from within the ischaemic region. In each field, cells were counted in the ischaemic region and the percentage of apoptotic cardiomyocytes was calculated.
GENOMIC DNA EXTRACTION AND AGAROSE GEL ELECTROPHORESIS
Procedures were based on previously published methods. 5 To assess genomic DNA fragmentation, rabbit hearts were rapidly removed after the prolonged ischaemia and reperfusion, and tissue samples from the left ventricle were homogenized. The ApoAlert™ ligation-mediated polymerase chain reaction (PCR) ladder assay kit (Clontech Laboratories, Inc., Palo Alto, California, USA) was used. DNA electrophoresis was carried out in 3% agarose.
STATISTICAL ANALYSIS
All measurements of infarct size, risk areas and apoptosis are expressed as group mean ± SEM. Changes in haemodynamics, apoptosis and infarct size variables were analysed by one-way repeated-measures analysis of variance to determine the effect of time, group and time × group interaction. If the global tests showed major interactions, post hoc comparisons between different time points within the same group or between different groups were performed using the t-test. P-values < 0.05 were considered to be statistically significant.
Results
Forty-eight rabbits were used in the study: each treatment group included eight animals.
HAEMODYNAMIC DATA
Values for heart rate, mean arterial blood pressure and rate-pressure product during the course of the experiment are given in Table 1 . During ischaemia and reperfusion, these parameters did not show significant differences among the experimental groups in the early and late phases. Thus, all of the groups were comparable with regard to the haemodynamic parameters, which constitute a major determinant of infarct size.
INFARCT SIZE
In the control group, the mean percentage of infarct area in the risk area was 42.8 ± 5.2% ( Fig. 2A) . Early edaravone (23.5 ± 3.3%) and immediate edaravone (24.5 ± 5.3%) were associated with significantly reduced infarct size (P < 0.01) compared with controls. However, when edaravone was given 5 min after the start of reperfusion, this protection was lost completely (percentage infarction averaged 39.6 ± 4.5%, 39.8 ± 6.5% and 38.7 ± 5.6% for doses of 3, 6 and 10 mg/kg, respectively). No significant difference in the mean percentage risk area in the left ventricle was observed among all the groups (Fig. 2B ).
PERCENTAGE OF CELLS WITH DNA FRAGMENTATION
Quantitative analysis of DNA fragmentation was performed using the TUNEL method at the single-cell level (Fig. 3) . DNA fragmentation was significantly decreased (P < 0.01) in the early edaravone (2.5 ± 1.8%) and immediate edaravone (3.2 ± 1.8%) groups compared with the control group A Fukuda, S Okubo, Y Tanabe et al. 
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DETECTION OF GENOMIC DNA FRAGMENTATION
DNA fragmentation was evaluated by agarose gel electrophoresis of ligation-mediated PCR with the DNA ladder assay (Fig. 4) . Genomic DNA extracted from ischaemic hearts produces A Fukuda, S Okubo, Y Tanabe et al. However, ischaemic left ventricle regions obtained from the control and late edaravone groups showed a typical DNA electrophoretic pattern characterized by mononucleosomal and oligonucleosomal DNA fragmentation.
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Discussion
The sudden influx of oxygen into hypoxic or anoxic cells during reperfusion induces the formation of oxygen free radicals. An increase in reactive oxygen species is associated with reperfusion injury, largely because of the modification of phospholipids and proteins leading to lipid peroxidation and oxidation of the thiol group. 6 Oxidative stress is caused by imbalance between oxidants and antioxidants, by a surplus of oxidative requirements, or by the depletion of antioxidants. In these situations, the generation of oxygen free radicals has been proposed as a major mechanism of reperfusion injury. 7, 8 The occurrence of apoptosis-programmed myocardial cell death can be detected during ischaemia-reperfusion. 9 Reactive oxygen species, including hydrogen peroxide, the superoxide radical and the hydroxyl radical, increase on reperfusion after ischaemia. 10, 11 Cardiac dysfunction in the delayed phase after acute myocardial infarction, i.e. left ventricular remodelling, suggests that reactive oxygen species, which have been implicated in cardiac pathophysiology, can FIGURE 4: Effect of edaravone treatment on DNA fragmentation. Extraction and electrophoresis of DNA from cardiac tissue samples were carried out using the ligationmediated polymerase chain reaction method. M, DNA ladder markers; Early, edaravone (3 mg/kg) IV 10 min before the start of reperfusion; Immediate, edaravone (3 mg/kg) IV immediately after the start of reperfusion; Late, edaravone (3, 6 or 10 mg/kg) IV 5 min after the start of reperfusion Effect of edaravone treatment on reperfusion injury trigger myocyte apoptosis by up-regulating pro-apoptotic proteins, such as Bax and caspases, and the mitochondria-dependent pathway. 12 In this study, we investigated whether cell damage such as necrosis or apoptosis was inhibited by edaravone, and the effect of the timing of edaravone administration on reperfusion injury.
Using the edaravone-treated rabbit ischaemia-reperfusion model, Wu et al. 13 showed that the infarct area was reduced by 60% with edaravone. On the basis of this result, we used the rabbit model. Our data imply that administration of a single bolus dose of edaravone 3 mg/kg in rabbits after 30 min of ischaemia of the left coronary artery followed by 3 h of reperfusion reduced the mean necrotic area of the post-ischaemic hearts from 42.8 ± 5.2% (control) to 23.5 ± 3.3% (early group) and 24.5 ± 5.3% (immediate group). In addition, edaravone treatment inhibited apoptosis when given before reperfusion (2.5 ± 1.8%) and immediately after the start of reperfusion (3.2 ± 1.8%) compared with the control group (15.0 ± 3.9%). The cardioprotective effects of edaravone, however, were attenuated when the agent was given 5 min after the initiation of reperfusion (for the infarction data, 42.8 ± 5.2% in the control versus 39.6 ± 4.5%, 39.8 ± 6.5% and 38.7 ± 5.6% for doses of 3, 6 and 10 mg/kg, respectively, in the late group, and for the apoptosis data, 15.0 ± 3.9% in the control versus 14.3 ± 3.3%, 14.6 ± 4.8% and 13.2 ± 4.1% for doses of 3, 6 and 10 mg/kg, respectively, in the late group).
These results indicate that edaravone is likely to attenuate myocardial damage following myocardial infarction in humans in a clinical setting. Previous animal studies reported that edaravone treatment before reperfusion prevented lethal reperfusion ventricular tachyarrhythmias and deter-iorating cardiac function after ischaemiareperfusion. 14 Tsujita et al. 15 reported the results of a pilot study in humans, finding that administration of edaravone (30 mg) before myocardial reperfusion may be associated with smaller infarcts and a better clinical outcome. In all previous reports regarding the cardioprotective effect on reperfusion injury of edaravone treatment, edaravone was given before reperfusion. The results of this study relating to edaravone treatment before reperfusion are similar to data in previous reports. However, although the administration of edaravone immediately after the start of reperfusion was associated with a reduction in the infarct area and the appearance of apoptotic cells, administration of edaravone after 5 min of reperfusion was not associated with cardioprotective effects. It is known that a massive influx of reactive oxygen species occurs after reperfusion, and it has been shown that the reperfusion injury due to reactive oxygen species can be inhibited by edaravone treatment given immediately upon initiation of reperfusion. However, administration of edaravone after 5 min of reperfusion does not have a cardioprotective effect. This result shows that an edaravone dose of 3, 6 or 10 mg/kg given after 5 min of reperfusion may not be high enough to prevent reperfusion injury.
It is not known how ischaemiareperfusion triggers apoptosis. Recent studies have shown that apoptotic cells are formed after the opening of a latent non-specific pore in the inner membrane of the mitochondria, known as the mitochondrial permeability transition pore. 16 -18 According to Rajesh et al., 19 protein located in the outer membrane of the mitochondria, was able to inhibit the mitochondrial permeability transition pore during reperfusion states. Although the antiapoptotic protein up-regulation and inhibition of mitochondrial permeability transition pore and cytochrome c release were not evaluated in the present study, cardioprotection against reperfusion injury was shown by treatment with edaravone when the agent was administered before or immediately after the start of reperfusion.
In conclusion, the free radical scavenger edaravone has a powerful cardioprotective effect against reperfusion injury. This effect is seen when edaravone is administered before or immediately after the initiation of reperfusion. However, edaravone does not have this protective effect when it is given 5 min after the initiation of reperfusion. It might therefore be inferred that this established strong anti-oxidative drug could be used safely to prevent reperfusion-induced injury in patients with acute myocardial infarction, subject to further research.
